Cantargia AB Asset Resilience Ratio

Latest as of September 2025: 0.00%

Cantargia AB asset resilience ratio. Cantargia AB (CANTA) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cantargia AB (CANTA) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

Skr358.89 Million
≈ $38.62 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Cantargia AB (2015–2024)

Asset resilience ratio of Cantargia AB from 2015 to 2024. This chart shows how Cantargia AB's Asset Resilience Ratio has changed over time. Read CANTA total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Cantargia AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cantargia AB balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Cantargia AB maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Cantargia AB Industry Peers by Asset Resilience Ratio

Compare Cantargia AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Cantargia AB Asset Resilience Ratio by Year (2015–2024)

Cantargia AB asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Cantargia AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.00% Skr0.00
≈ $0.00
Skr170.43 Million
≈ $18.34 Million
--
2023-12-31 24.59% Skr55.00 Million
≈ $5.92 Million
Skr223.71 Million
≈ $24.07 Million
-25.35pp
2022-12-31 49.94% Skr237.09 Million
≈ $25.52 Million
Skr474.80 Million
≈ $51.10 Million
-2.05pp
2021-12-31 51.99% Skr312.06 Million
≈ $33.58 Million
Skr600.24 Million
≈ $64.60 Million
+29.30pp
2020-12-31 22.69% Skr210.02 Million
≈ $22.60 Million
Skr925.51 Million
≈ $99.60 Million
-43.56pp
2019-12-31 66.25% Skr110.02 Million
≈ $11.84 Million
Skr166.06 Million
≈ $17.87 Million
+13.57pp
2018-12-31 52.68% Skr90.32 Million
≈ $9.72 Million
Skr171.44 Million
≈ $18.45 Million
+8.96pp
2017-12-31 43.72% Skr120.00 Million
≈ $12.91 Million
Skr274.45 Million
≈ $29.54 Million
+24.91pp
2016-12-31 18.81% Skr8.94 Million
≈ $961.76K
Skr47.51 Million
≈ $5.11 Million
-28.58pp
2015-12-31 47.39% Skr14.87 Million
≈ $1.60 Million
Skr31.38 Million
≈ $3.38 Million
--
pp = percentage points

About Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$44.55 Million
Skr413.94 Million SEK
Market Cap Rank
#22145 Global
#415 in Sweden
Share Price
Skr1.67
Change (1 day)
-3.20%
52-Week Range
Skr1.28 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more